Got Stocks from QualityStocks Ones To Watch

Ohr Pharmaceutical, Inc. (OHRP)

Trading on the OTCBB, Ohr Pharmaceutical, Inc. is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The company is focusing on two lead compounds. One is Squalamine eye drops for the treatment of the wet form of age-related macular degeneration. The other is OHR/AVR118 for the treatment of cancer cachexia, currently undergoing investigation in a Phase II trial.

The Company's Squalamine is a first-in-class systemic intracellular anti-angiogenic drug with a novel mechanism of action. Its ophthalmic formulation, Evizon™, has undergone evaluation against the wet form of age-related macular degeneration. In Phase II trials, in which no drug-related ocular or systemic effects were observed, stabilization or improvement in visual activity was observed in the vast majority of patients, with both early and advanced lesions responding.

The company's OHR/AVR118 is a broad-spectrum peptide nucleic acid (PNA) immunomodulator drug. It is available in a preservative-free formulation that is stable at room temperature. The drug is currently undergoing evaluation in a Phase IIb clinical study for Cancer Cachexia at a leading Cancer Centre in Canada. Cancer Cachexia is a severe wasting disorder characterized by weight loss, muscle atrophy, fatigue, weakness, and significant loss of appetite. This disorder is often seen in late stage Cancer patients.

Ohr Pharmaceutical's President, Chief Executive Officer, and Director is Dr. Irach Taraporewala. Dr. Taraporewala has more than 30 years' experience in drug development and regulatory affairs. He was formerly the Vice President of Regulatory Affairs and Clinical Research at Austin, Texas-based Mystic Pharmaceuticals Inc. While there, he led the regulatory strategy for Mystic Pharmaceuticals' ophthalmic and intranasal drug products and drug delivery systems.